Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) Receives $9.50 Average PT from Analysts

Shares of Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) have received a consensus rating of “Buy” from the seven analysts that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $6.60.

Several equities analysts have commented on ETTX shares. BMO Capital Markets dropped their price target on shares of Entasis Therapeutics from $15.00 to $5.00 and set an “outperform” rating for the company in a research note on Friday, May 8th. Wedbush restated an “outperform” rating and issued a $7.00 price target on shares of Entasis Therapeutics in a research note on Sunday, June 21st. CSFB restated an “outperform” rating and issued a $8.00 price target on shares of Entasis Therapeutics in a research note on Sunday, June 21st. Zacks Investment Research downgraded shares of Entasis Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, June 16th. Finally, Credit Suisse Group restated an “outperform” rating and issued a $8.00 price target on shares of Entasis Therapeutics in a research note on Sunday, June 21st.

In other news, major shareholder Innoviva, Inc. bought 12,677,490 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was purchased at an average price of $2.50 per share, for a total transaction of $31,693,725.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 15.40% of the company’s stock.

A hedge fund recently raised its stake in Entasis Therapeutics stock. Renaissance Technologies LLC increased its position in shares of Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) by 42.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,300 shares of the company’s stock after purchasing an additional 7,600 shares during the period. Renaissance Technologies LLC owned 0.19% of Entasis Therapeutics worth $126,000 at the end of the most recent quarter. Institutional investors own 56.90% of the company’s stock.

NASDAQ ETTX traded up $0.07 on Friday, reaching $2.94. The stock had a trading volume of 74,956 shares, compared to its average volume of 143,396. The firm has a market capitalization of $41.94 million, a price-to-earnings ratio of -0.84 and a beta of 2.09. The company has a quick ratio of 5.67, a current ratio of 5.67 and a debt-to-equity ratio of 0.04. Entasis Therapeutics has a 12-month low of $1.75 and a 12-month high of $9.25. The stock has a fifty day moving average price of $2.74 and a two-hundred day moving average price of $3.83.

Entasis Therapeutics (NASDAQ:ETTX) last announced its earnings results on Thursday, May 7th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.15). Sell-side analysts forecast that Entasis Therapeutics will post -2.27 earnings per share for the current fiscal year.

Entasis Therapeutics Company Profile

Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.

Recommended Story: Catch-Up Contributions

Analyst Recommendations for Entasis Therapeutics (NASDAQ:ETTX)

Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.